- Neutrolis Inc. will present **early evidence for human proof of concept** of its exDNASE™ therapeutic platform at the American College of Rheumatology (ACR) Convergence 2025.  **[1512886_ee22ba4f1290425ca49e1cced3cc484a_0]** 
- The podium presentation is scheduled for **October 29, 2025**, from 8:45 AM - 9:00 AM CT.  **[1512886_ee22ba4f1290425ca49e1cced3cc484a_0]** 
- The data validates **DNASE1L3 as a novel therapeutic approach** to degrade and inactivate Neutrophil Extracellular Traps (NETs), which are central drivers of systemic inflammatory disorders.  **[1512886_ee22ba4f1290425ca49e1cced3cc484a_0]** 
- This marks an **important milestone** for Neutrolis, underscoring the potential to create a new class of transformational, disease-modifying therapies for conditions such as lupus and rheumatoid arthritis.  **[1512886_ee22ba4f1290425ca49e1cced3cc484a_0]**

NEUTRA (NTRR)